Literature DB >> 10566718

A single dose of ceftriaxone administered 30 minutes before percutaneous endoscopic gastrostomy significantly reduces local and systemic infective complications.

A J Dormann1, B Wigginghaus, H Risius, F Kleimann, A Kloppenborg, T Grünewald, H Huchzermeyer.   

Abstract

OBJECTIVE: The aim of this study was to determine the efficacy of antibiotic prophylaxis in percutaneous endoscopic gastrostomy (PEG).
METHODS: An open prospective, randomised, multicenter study was conducted in 141 patients; 72 received ceftriaxone 1 g i.v. 30 min preintervention, and 69 received no study medication. A standardized protocol was followed for PEG preparation, insertion, and aftercare; all patients received a 15-Fr gastrostomy tube. Follow-up of local and systemic infection and clinical course was continued to postintervention day 10. An aggregate erythema and exudation score >3 or the presence of pus was taken as indicative of peristomal infection. The pharmacoeconomics of antibiotic use were also examined.
RESULTS: In no-prophylaxis patients, wound infection rates were 25% on day 4 and 26.4% on day 10, versus 10.1% (p = 0.03) and 14.5% (p = 0.10), respectively, in prophylaxis patients. Results were disproportionally better in tumor patients: systemic infection rates were 16.7% versus 5.8% in no-prophylaxis versus prophylaxis patients (p = 0.045), and overall infection rates 38.9% versus 17.4%, respectively (p = 0.046). Pneumonia was more frequent in patients with underlying neurological disease. Antibiotic costs were the same in both groups (p = 0.792).
CONCLUSIONS: Single dose ceftriaxone 1 g is an effective prophylaxis against local and systemic infection after PEG.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10566718     DOI: 10.1111/j.1572-0241.1999.01523.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  13 in total

1.  Antibiotic prophylaxis after percutaneous endoscopic gastrotomy insertion. All encompassing study is needed.

Authors:  S Sanders; M J Carter
Journal:  BMJ       Date:  2000-03-25

2.  [The value of percutaneous endoscopic gastrostomy in ENT tumor patients].

Authors:  K Mantsopoulos; M Koch; J Zenk; H Iro
Journal:  HNO       Date:  2010-04       Impact factor: 1.284

Review 3.  Percutaneous endoscopic gastrostomy: a safe and effective bridge for enteral nutrition in neurological or non-neurological conditions.

Authors:  Rasim Gencosmanoglu
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

4.  Complication rate lower after percutaneous endoscopic gastrostomy than after surgical gastrostomy: a prospective, randomized trial.

Authors:  M Ljungdahl; M Sundbom
Journal:  Surg Endosc       Date:  2006-07-24       Impact factor: 4.584

5.  A guide to antibiotics for the interventional radiologist.

Authors:  Ali Zarrinpar; Robert K Kerlan
Journal:  Semin Intervent Radiol       Date:  2005-06       Impact factor: 1.513

6.  [Indications and complications of percutaneous endoscopic gastrostomy].

Authors:  Gerhard Aschl; Andreas Kirchgatterer; Stephan Allinger; Max Hinterreiter; Dietmar Hubner; Wolfgang Kranewitter; Bernhard Stadler; Ludwig Wimmer; Peter Knoflach
Journal:  Wien Klin Wochenschr       Date:  2003-02-28       Impact factor: 1.704

Review 7.  Complications of and controversies associated with percutaneous endoscopic gastrostomy: report of a case and literature review.

Authors:  Jonathan Z Potack; Sita Chokhavatia
Journal:  Medscape J Med       Date:  2008-06-17

Review 8.  [Endoscopic and surgical procedures for enteral nutrition].

Authors:  I Wallstabe; A Tiedemann; I Schiefke; A Weimann
Journal:  Chirurg       Date:  2013-07       Impact factor: 0.955

Review 9.  Systemic antimicrobial prophylaxis for percutaneous endoscopic gastrostomy.

Authors:  Allyson Lipp; Gail Lusardi
Journal:  Cochrane Database Syst Rev       Date:  2013-11-14

10.  Local infection after placement of percutaneous endoscopic gastrostomy tubes: a prospective study evaluating risk factors.

Authors:  Y Zopf; P Konturek; A Nuernberger; J Maiss; J Zenk; H Iro; E G Hahn; D Schwab
Journal:  Can J Gastroenterol       Date:  2008-12       Impact factor: 3.522

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.